In June 2025, the US Food and Drug Administration recommended monovalent JN.1 lineage-based COVID-19 vaccines, preferentially using the LP.8.1 strain, for 2025–2026 COVID-19 vaccine formulations [47]. This evidence concerns the gene ERMN and COVID-19.